Adalimumab treatment in Crohn’s disease: an overview of long-term efficacy and safety in light of the EXTEND trial

References

• Peyrin-BirouletLLoftusEVJrColombelJFSandbornWJThe natural history of adult Crohn’s disease in population-based cohortsAm J Gastroenterol201010528929719861953
   PubMed Web of Science ®Google Scholar
• LangholzEUlcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosisDan Med Bull19994640041510605619
   PubMed Web of Science ®Google Scholar
• BestWRBecktelJMSingletonJWKernFJrDevelopment of a Crohn’s disease activity index. National Cooperative Crohn’s Disease StudyGastroenterol1976703439444
   PubMed Web of Science ®Google Scholar
• SummersRWSwitzDMSessionsJTJrNational Cooperative Crohn’s Disease Study: results of drug treatmentGastroenterology1979774 Pt 284786938176
   PubMed Web of Science ®Google Scholar
• MaryJYModiglianiRDevelopment and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)Gut1989309839892668130
   PubMed Web of Science ®Google Scholar
• Van DullemenHMvan DeventerSJHommesDWTreatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology19951091291357797011
   PubMed Web of Science ®Google Scholar
• RutgeertsPDiamondRHBalaMScheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s diseaseGastrointest Endosc20066343344216500392
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWSONIC Study GroupInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med20103621383139520393175
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRACCENT I Study GroupMaintenance infliximab for Crohn’s disease: the ACCENT I randomized trialLancet20023591541154912047962
   PubMed Web of Science ®Google Scholar
• BaertFJMoortgatLVan AsscheGABelgian Inflammatory Bowel Disease Research GroupNorth-Holland Gut ClubMucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s diseaseGastroenterology201013846346819818785
   PubMed Web of Science ®Google Scholar
• D’HaensGNomanMBaertFEndoscopic healing after infliximab treatment for Crohn’s disease provides a longer time to relapseGastroenterology2002122Suppl 4A100
   Web of Science ®Google Scholar
• SchnitzlerFFidderHFerranteMMucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s diseaseInflamm Bowel Dis2009151295130119340881
   PubMed Web of Science ®Google Scholar
• RutgeertsPVermeireSVan AsscheGMucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Gut20075645345517369375
   PubMed Web of Science ®Google Scholar
• D’HaensGRFedorakRLémannMEndpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s diseaseInflamm Bowel Dis2009151599160419653291
   PubMed Web of Science ®Google Scholar
• TaylorKMIrvingPMOptimization of conventional therapy in patients with IBDNat Rev Gastroenterol Hepatol2011864665621970871
   PubMed Web of Science ®Google Scholar
• BlonskiWBuchnerAMLichtensteinGRInflammatory bowel disease therapy: current state-of-the-artCurr Opin Gastroenterol20112734635721654383
   PubMed Web of Science ®Google Scholar
• ClarkMColombelJFFeaganBCAmerican Gastroenterological Association Consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006Gastroenterology200713331233917631151
   PubMed Web of Science ®Google Scholar
• EtcheversMJOrdaIRichartEOptimizing the use of tumour necrosis factor inhibitors in Crohn’s disease. A practical approachDrugs20107010912020108987
   PubMed Web of Science ®Google Scholar
• GoelNStephensSCertolizumab pegolMAbs2010213714720190560
   PubMed Web of Science ®Google Scholar
• RutgeertsPAsscheGVSandbornWJAdalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trialGastroenterology20121421102111122326435
   PubMed Web of Science ®Google Scholar
• ThomsonABGuptaMFreemanHUse of the tumor necrosis factor-blockers for Crohn’s diseaseWorld J Gastroenterol2012184823485423002356
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther200811724427918155297
   PubMed Web of Science ®Google Scholar
• Van DeventerSTumour necrosis factor and Crohn’s diseaseGut1997404434489176068
   PubMed Web of Science ®Google Scholar
• SandsBEWhy do anti-tumor necrosis factor antibodies work in Crohn’s disease?Rev Gastroenterol Disord20044S10S1715580148
   PubMedGoogle Scholar
• Di SabatinoACiccocioppoRCinqueBDefective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s diseaseGut200453707714684579
   PubMed Web of Science ®Google Scholar
• BestWRBecktelJMSingletonJWKernFJrDevelopment of a Crohn’s disease activity index: National Cooperative Crohn’s Disease StudyGastroenterology1976704394441248701
   PubMed Web of Science ®Google Scholar
• DaveMLoftusEVMucosal healing in inflammatory bowel disease – a true paradigm of success?Gastroenterol Hepatol201282938
   PubMedGoogle Scholar
• SandsBAndersonFBernsteinCInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med200435087688514985485
   PubMed Web of Science ®Google Scholar
• ThiaKTSandbornWJLewisJDDefining the optimal response criteria for the Crohn’s disease activity index for induction studies in patients with mildly to moderately active Crohn’s diseaseAm J Gastroenterol20081033123313118786111
   PubMed Web of Science ®Google Scholar
• D’HaensGSandbornWJFeaganBGA review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitisGastroenterology200713276378617258735
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGHanauerSBA review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s diseaseGastroenterology200212251253011832465
   PubMed Web of Science ®Google Scholar
• DapernoMD’HaensGVan AsscheGDevelopment and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CDGastrointest Endosc20046050551215472670
   PubMed Web of Science ®Google Scholar
• SchroederKWTremaineWJIlstrupDMCoated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized studyN Engl J Med1987317162516293317057
   PubMed Web of Science ®Google Scholar
• RutgeertsPGeboesKVantrappenGBeylsJKerremansRHieleMPredictability of the postoperative course of Crohn’s diseaseGastroenterology1990999569632394349
   PubMed Web of Science ®Google Scholar
• VillanacciVAntonelliEGeboesKCasellaGBassottiGHistological healing in inflammatory bowel disease: a still unfulfilled promiseWorld J Gastroenterol20131996897823467585
   PubMed Web of Science ®Google Scholar
• GeboesKDalleIInfluence of treatment on morphological features of mucosal inflammationGut200250Suppl 3III37III4211953331
   PubMedGoogle Scholar
• GeboesKRiddellROstAJensfeltBPerssonTLöfbergRA reproducible grading scale for histological assessment of inflammation in ulcerative colitisGut20004740440910940279
   PubMed Web of Science ®Google Scholar
• FazioVWMarchettiFChurchMEffect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trialAnn Surg19962245635718857860
   PubMed Web of Science ®Google Scholar
• KornbluthASacharDBUlcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol2004991371138515233681
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med20013451098110411596589
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKBiologic treatment of rheumatoid arthritis and the risk of malignancyArthritis Rheum2007562886289517729297
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudKHeart failure in rheumatoid arthritis: rates, predictors, and the effect of anti tumor necrosis factor therapyAm J Med200411630531114984815
   PubMed Web of Science ®Google Scholar
• BurmesterGRMeasePDijkmansBACAdalimumab safety and mortality rates from global trials of six immune mediated inflammatory diseasesAnn Rheum Dis2009681863186919147611
   PubMed Web of Science ®Google Scholar
• MohanNEdwardsETCuppsTRDemyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritidesArthritis Rheum2001442862286911762947
   PubMed Web of Science ®Google Scholar
• BurmesterGRPanaccioneRGordonKBMcIlraithMJLacerdaAPAdalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s diseaseAnn Rheum Dis20137251752422562972
   PubMed Web of Science ®Google Scholar
• ZhangDXiongBLiXXuTYuMMeta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitorsHepatogastroenterology20132360
   Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology200613032333316472588
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trialAnn Intern Med200714682983817470824
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology2007132526517241859
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut2007561232123917299059
   PubMed Web of Science ®Google Scholar
• OlaisonBSjodahlRTagessonCGlucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not endoscopically viewed inflammationGut1990313253282323598
   PubMed Web of Science ®Google Scholar
• LiuYWuEQBensimonAGCost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritisAdv Ther20122962063422843208
   PubMed Web of Science ®Google Scholar
• LoftusEVJrJohnsonSJYuAPWuEQChaoJMulaniPMCost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s diseaseEur J Gastroenterol Hepatol2009211302130919465858
   PubMed Web of Science ®Google Scholar
• YuAPCabanillaLAWuEQMulaniPMChaoJThe costs of Crohn’s disease in the United States and other Western countries: a systematic reviewCurr Med Res Opin20072431932818067689
   PubMed Web of Science ®Google Scholar
• BinionDGLouisEOldenburgBEffect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysisCan J Gastroenterol20112549249621912760
   PubMed Web of Science ®Google Scholar
• FerranteMVan AsscheGMedical therapy and mucosal healingCurr Drug Targets2012131294129922664087
   PubMed Web of Science ®Google Scholar
• RismoROlsenTCiuGThe effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn’s diseaseScand J Gastroenterol2012471200121022861799
   PubMed Web of Science ®Google Scholar
• ColombelJFLemannMBouhnikYEndoscopic mucosal improvement in patients with active Crohn’s disease treated with certolizumab pegol: week 10 and 54 results of the MUSIC trialGastroenterology2010138S166
   Web of Science ®Google Scholar
• BjorkestenANieminenUSipponenTMucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn’s diseaseScand J Gastroenterol20134854355123477356
   PubMed Web of Science ®Google Scholar
• SandbornWJColombelJFPanesJExploring the use of adalimumab for patients with moderate Crohn’s disease: subanalyses from induction and maintenance trialsJ Crohns Colitis3182013 [Epub ahead of print.] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23517933Accesssed August 15, 2013
   Web of Science ®Google Scholar